# Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy

Study · id `cardio:ct-nct02979561` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02979561](<https://clinicaltrials.gov/study/NCT02979561>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02979561

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT02979561. Randomized; no masking; primary purpose treatment. Start 2016-10 (registry gives no type); primary completion 2018-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT02979561, source copy `cardio:ctgov-nct02979561-2016-12-20`, retrieved 2026-10-31)
- Start date: 2016-10 (registry gives no type) (ClinicalTrials.gov record NCT02979561, source copy `cardio:ctgov-nct02979561-2016-12-20`, retrieved 2026-10-31)
- Primary completion: 2018-06 (anticipated) (ClinicalTrials.gov record NCT02979561, source copy `cardio:ctgov-nct02979561-2016-12-20`, retrieved 2026-10-31)
- Completion: 2018-06 (anticipated) (ClinicalTrials.gov record NCT02979561, source copy `cardio:ctgov-nct02979561-2016-12-20`, retrieved 2026-10-31)
- Countries: Russia (ClinicalTrials.gov record NCT02979561, source copy `cardio:ctgov-nct02979561-2016-12-20`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02979561-2016-12-20`, retrieved 2026-10-31)

## The registry's words

- Brief title: Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy
- Acronym: Re-Spire
- Condition: Angiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy
- Intervention (Drug): Dabigatran Etexilate
- Intervention (Drug): Warfarin
- Lead sponsor: Meshalkin Research Institute of Pathology of Circulation
- Lead sponsor class: NETWORK

## Connected pages

- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)
- Registry lists this organization as the lead sponsor: Meshalkin Research Institute of Pathology of Circulation (`cardio:org-meshalkin-research-institute-of-pathology-of-circulation`)

## Provenance

Content hash: a01fa7cdbc93d5b55a42fb126c733c643bf58876cd8481f9072ed391a893e197
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
